Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | See Remarks | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neumora Therapeutics, Inc.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,750 |
Ending reported balance
After 2026-08-21 transaction · row 7
4 source rows · reconciled sequenceRow 1 · 2026-08-20 · Exercise / conversion · Acquired 67,741 · Balance 116,491 Row 2 · 2026-08-20 · Sale · Disposed 67,741 · Balance 48,750 F1: This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 6 · 2026-08-21 · Exercise / conversion · Acquired 20,553 · Balance 69,303 Row 7 · 2026-08-21 · Sale · Disposed 20,553 · Balance 48,750 F7: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Last balance in matching sequence
After 2026-08-21 transaction · row 9
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 3 · 2026-08-20 · Exercise / conversion · Acquired 21,685 · Balance 21,685 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 4 · 2026-08-20 · Exercise / conversion · Acquired 45,026 · Balance 66,711 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 5 · 2026-08-20 · Sale · Disposed 66,711 · Balance 0 F2: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 8 · 2026-08-21 · Exercise / conversion · Acquired 21,055 · Balance 21,055 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 9 · 2026-08-21 · Sale · Disposed 21,055 · Balance 0 F8: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2034-02-14 | Direct | 109,527 |
Reported balance
After 2026-08-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-20 · Exercise / conversion · Disposed 67,741 · Balance 109,527 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20 | Direct | 200,000 |
Reported balance
After 2026-08-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-20 · Grant · Acquired 200,000 · Balance 200,000 F6: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2034-02-14 | Direct | 88,974 |
Reported balance
After 2026-08-21 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-21 · Exercise / conversion · Disposed 20,553 · Balance 88,974 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2033-01-19 | IndirectSee footnote | 0 |
Reported balance
After 2026-08-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-20 · Exercise / conversion · Disposed 45,026 · Balance 0 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2031-09-20 | IndirectSee footnote | 115,853 |
Reported balance
After 2026-08-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-20 · Exercise / conversion · Disposed 21,685 · Balance 115,853 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2031-09-20 | IndirectSee footnote | 94,798 |
Reported balance
After 2026-08-21 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-21 · Exercise / conversion · Disposed 21,055 · Balance 94,798 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F5: The stock option is fully vested and exercisable.
F6: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F7: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 30,089 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.36 · Expires 2026-08-07 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 67,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 11,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 28,130 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 7,040 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2028-02-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2029-11-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 28,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 6,250 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-20 · Disposition to issuer · Disposed 574 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-20 · Disposition to issuer · Disposed 2,814 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-02-20 · Disposition to issuer · Disposed 708 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-20 · Disposition to issuer · Disposed 22,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-02-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 72,221 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 13 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,221 Underlying: Common Stock · 72,221 shares Expires 2033-06-23 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 136,210 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 12 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 136,210 Underlying: Common Stock · 136,210 shares Expires 2033-01-19 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 207,901 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 11 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,901 Underlying: Common Stock · 207,901 shares Expires 2033-01-19 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 137,538 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 10 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 137,538 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 40,890 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 9 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,890 Underlying: Common Stock · 40,890 shares Expires 2031-09-20 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2035-02-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 195,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,000 shares Expires 2034-02-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 29,737 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 29,737 shares Expires 2033-06-23 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 72,221 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,221 shares Expires 2033-06-23 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 136,210 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 136,210 shares Expires 2033-01-19 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 207,901 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 207,901 shares Expires 2033-01-19 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 137,538 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 2 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,890 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,890 shares Expires 2031-09-20 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:13 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 8,565 | $1.68 | $14,347.23 |
DisclosureSEC source: 0001610717-25-000029 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,935 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation. F2 · price: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.705, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 195,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 15 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-02-14 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 29,737 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 14 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 29,737 Underlying: Common Stock · 29,737 shares Expires 2033-06-23 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 72,221 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 13 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,221 Underlying: Common Stock · 72,221 shares Expires 2033-06-23 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 136,210 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 12 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 136,210 Underlying: Common Stock · 136,210 shares Expires 2033-01-19 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 207,901 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 11 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,901 Underlying: Common Stock · 207,901 shares Expires 2033-01-19 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 137,538 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 10 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 137,538 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 40,890 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 9 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,890 Underlying: Common Stock · 40,890 shares Expires 2031-09-20 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 195,000 | Not disclosed Strike: $18.07 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,000 shares Expires 2034-02-14 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 29,737 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 29,737 shares Expires 2033-06-23 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 72,221 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,221 shares Expires 2033-06-23 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 136,210 | Not disclosed Strike: $6.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 136,210 shares Expires 2033-01-19 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 207,901 | Not disclosed Strike: $6.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 207,901 shares Expires 2033-01-19 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 137,538 | Not disclosed Strike: $4.24 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,890 | Not disclosed Strike: $4.24 | Not disclosed |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 2 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,890 shares Expires 2031-09-20 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0000950170-25-022320 · ownership.xml · derivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 29,737 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 29,737 Underlying: Common Stock · 29,737 shares Expires 2033-06-22 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F1 · ownership.nature: Shares held by Aurora Family Trust. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 29,737 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,221 Underlying: Common Stock · 29,737 shares Expires 2033-06-22 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F5 · balance_after: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 136,210 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 136,210 Underlying: Common Stock · 136,210 shares Expires 2033-01-18 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F1 · ownership.nature: Shares held by Aurora Family Trust. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 136,210 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,901 Underlying: Common Stock · 136,210 shares Expires 2033-01-18 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F4 · balance_after: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 137,538 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 137,538 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F1 · ownership.nature: Shares held by Aurora Family Trust. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftStock Option (Right to Buy) · Derivative | 137,538 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001610717-24-000475 · form4.xml · derivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,890 Underlying: Common Stock · 137,538 shares Expires 2031-09-20 F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F3 · balance_after: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 21:00 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftCommon Stock | 114,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000222 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 F1 · kind: On April 22, 2024, the Reporting Person transferred, for no consideration, 114,703 shares of Common Stock to Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:20 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0001610717-24-000068 · form4.xml · derivative · entry 2 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:20 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 97,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000068 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,203 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 14 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 13 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 12 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 11 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 708 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 2,814 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 10 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,814 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 9 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 574 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerEmployee Stock Options (Right to buy) · Derivative | 28,000 | Not disclosed Strike: $8.05 | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2029-11-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerEmployee Stock Options (Right to buy) · Derivative | 50,000 | Not disclosed Strike: $6.97 | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-02-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerEmployee Stock Options (Right to buy) · Derivative | 7,040 | Not disclosed Strike: $28.25 | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,040 shares Expires 2028-02-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerEmployee Stock Options (Right to buy) · Derivative | 28,130 | Not disclosed Strike: $28.25 | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,130 shares Expires 2028-02-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerEmployee Stock Options (Right to buy) · Derivative | 11,500 | Not disclosed Strike: $33.84 | Not disclosed |
DisclosureSEC source: 0001562180-20-001623 · primarydocument.xml · derivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · Chief Scientific Affairs Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2027-02-16 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.